GlaxoSmithKline Plc and Sanofi SA said on Tuesday they would develop a vaccine to fight the fast-spreading coronavirus.
The drugmakers said they expect to start clinical trials for the vaccine in the second half of this year. If successful, the vaccine would be available in the second half of 2021.
The adjuvanted vaccine will be developed by combining Sanofi’s S-protein COVID-19 antigen and GSK’s pandemic adjuvant technology.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Coronavirus live updates: Sanofi, GSK working on vaccine, Amazon fires two outspoken employeesNew York City will purchase 100,000 coronavirus test kits per week from a mix of local contractors and an Indiana-based company, Mayor Bill de Blasio announced today. Follow along with the latest coronavirus news here:
続きを読む »
Sanofi partners with GSK for developing coronavirus vaccineClinical trials of the vaccine will start this year, Sanofi CEO Paul Hudson said.
続きを読む »
Sanofi partners with GSK for developing coronavirus vaccineClinical trials of the vaccine will start this year, Sanofi CEO Paul Hudson said.
続きを読む »
Human trials of two coronavirus vaccines start in ChinaThere is currently no vaccine to prevent COVID-19.
続きを読む »
Could old vaccines for other germs protect against COVID-19?“The scientific rationale I think is quite logical,” one researcher said.
続きを読む »